{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:25:37Z","timestamp":1790745937229,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis for patients with relapsed and\/or refractory (R\/R) non-Hodgkin\u2019s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatment of these cancers, AFM11 is a tetravalent, bispecific humanised recombinant antibody construct (TandAb\u00ae) designed to bind to human CD19 and CD3 and lead to the activation of T cells inducing apoptosis and killing of malignant B cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two open-label, multicentre, dose-escalation phase 1 studies evaluated the safety, pharmacokinetics and activity of AFM11 in patients with R\/R CD19-positive B cell NHL (AFM11-101) and in patients with CD19\u2009+\u2009B-precursor Philadelphia-chromosome negative ALL (AFM11-102). Adverse events (AEs) were assessed and recorded; imaging (NHL) or bone marrow assessment (ALL) were used to evaluate response. Additional pharmacodynamic assays undertaken included cytokine release analysis and B-cell and T-cell depletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In AFM11-101, 16 patients with R\/R NHL received AFM11 in five different dose cohorts. Of which, 14 experienced drug-related treatment-emergent AEs (TEAEs) [including five serious AEs (SAEs)], five patients experienced dose-limiting toxicity (DLT) and ten patients discontinued the study. The high number of neurological events led to a decrease in infusion frequency during the study. No objective response to treatment was observed. In AFM11-102, 17 patients with R\/R ALL received AFM11 in six different dose cohorts. Thirteen patients experienced drug-related TEAEs (including four SAEs), DLTs occurred in two patients and five patients discontinued the study. An objective response was recorded in three patients. The maximum tolerated dose could not be determined in either study due to early termination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AFM11 treatment was associated with frequent neurological adverse reactions that were severe in some patients. In ALL, some signs of activity, albeit short-lived, were observed whereas no activity was observed in patients with NHL; therefore, further clinical development was terminated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02106091\">NCT02106091<\/jats:ext-link>\n                      . Safety Study to Assess AFM11 in Patients With Relapsed and\/or Refractory CD19 Positive B-cell NHL. Registered April 2014.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02848911\">NCT02848911<\/jats:ext-link>\n                      . Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL. Registered July 2016.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06982-7","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T06:04:17Z","timestamp":1672725857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies"],"prefix":"10.1186","volume":"24","author":[{"given":"Max","family":"Topp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dlugosz-Danecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander B.","family":"Skotnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Salogub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Pietzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Strassz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Alland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"6982_CR1","unstructured":"Wild C, Weiderpass E, Stewart B, editors. World cancer report: cancer research for cancer prevention. Lyon: International Agency for Research on Cancer;\u00a02020.\u00a0http:\/\/publications.iarc.fr\/586."},{"key":"6982_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CMAR.S34273","volume":"5","author":"MP Chao","year":"2013","unstructured":"Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin\u2019s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251\u201369.","journal-title":"Cancer Manag Res"},{"key":"6982_CR3","unstructured":"National Institutes of Health. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Leukemia \u2013 Acute Lymphocytic Leukemia (ALL). https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html."},{"issue":"3","key":"6982_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood"},{"issue":"12","key":"6982_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333.","journal-title":"Haematologica"},{"issue":"1","key":"6982_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"6982_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","volume":"5","author":"TF Tedder","year":"2009","unstructured":"Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):572\u20137.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"6982_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4161\/mabs.21338","volume":"4","author":"O Hammer","year":"2012","unstructured":"Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs. 2012;4(5):571\u20137.","journal-title":"MAbs"},{"issue":"3","key":"6982_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","volume":"7","author":"U Reusch","year":"2015","unstructured":"Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584\u2013604.","journal-title":"MAbs"},{"issue":"1","key":"6982_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36.","journal-title":"Exp Hematol Oncol"},{"key":"6982_CR11","first-page":"225","volume":"5","author":"A Raufi","year":"2013","unstructured":"Raufi A, Ebrahim AS, Al-Katib A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res. 2013;5:225\u201333.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"6982_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","volume":"16","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, et al. A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(3):139\u201345.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6982_CR13","unstructured":"Amgen. Blincyto prescribing information. 2020.\u00a0Available at\u00a0https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf.\u00a0"},{"issue":"9","key":"6982_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"15","key":"6982_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89(15):1138\u201347.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6982_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6982_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334\u201342.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"6982_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"key":"6982_CR19","volume-title":"Kymriah prescribing information","author":"Novartis","year":"2020","unstructured":"Novartis. Kymriah prescribing information. 2020.\u00a0Available at:\u00a0https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/kymriah.pdf."},{"key":"6982_CR20","volume-title":"Yescarta prescribing information","author":"Kite Pharma","year":"2021","unstructured":"Kite Pharma. Yescarta prescribing information. 2021.\u00a0Available at:\u00a0https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf."},{"issue":"7776","key":"6982_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45\u201356.","journal-title":"Nature"},{"key":"6982_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fimmu.2016.00235","volume":"7","author":"IS Schuster","year":"2016","unstructured":"Schuster IS, Coudert JD, Andoniou CE, Degli-Esposti MA. \u201cNatural regulators\u201d: NK cells as modulators of T cell immunity. Front Immunol. 2016;7:235.","journal-title":"Front Immunol"},{"issue":"26","key":"6982_CR23","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024\u201331.","journal-title":"Blood"},{"issue":"21","key":"6982_CR24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2019004701","volume":"136","author":"NL Bartlett","year":"2020","unstructured":"Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401\u20139.","journal-title":"Blood"},{"issue":"5","key":"6982_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","volume":"11","author":"K Ellwanger","year":"2019","unstructured":"Ellwanger K, Reusch U, Fucek I, Wingert S, Ross T, M\u00fcller T, et al. Redirected optimized cell killing (ROCK\u00ae): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. MAbs. 2019;11(5):899\u2013918.","journal-title":"MAbs"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06982-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T19:05:17Z","timestamp":1673031917000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06982-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06982-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1113841\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both studies were conducted in accordance with International Council for Harmonisation, Good Clinical Practice, the Declaration of Helsinki, the European Union Clinical Trials Directive 2001\/20\/EC, the GCP Directive 2005\/28\/EC, the requirements of local IEC\/IRB, the US Code of Federal Regulations, Title 21 CFR Part 50, and the appropriate regulatory requirements in the countries where the studies were conducted. All patients provided informed consent in both studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SES, KP and UG are employees of Affimed GmbH. AS and LA were employees of Affimed GmbH at the time of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}